-
GEN – Genetic Engineering & Biotechnology News3 months ago
After Buying HUB and Partnering with Promega, MilliporeSigma Charts Growth Path in Organoids
Drug developers and their contract development and manufacturing organizations (CDMOs) moving away from animal testing—whether for financial, regulatory, or moral reasons—are increasingly finding an alternative in...
-
Synthetic Biology & Advanced Compound Production3 months ago
eXoZymes’ Cell-Free Biomanufacturing Platform Gets Positive Feedback from Cayman Chemical
eXoZymes’ Cell-Free Biomanufacturing Platform Gets Positive Feedback from Cayman Chemical
-
BioPharma Dive – AI / Data3 months agoRBC: Revolution, Xenon, Arrowhead among top takeover targets
As part of a larger review, analyst Leonid Timashev identified 13 companies that could see deal interest as well as more than half a dozen poised...
-
BioPharma Dive – AI / Data3 months agoJ&J wins FDA nod for psoriasis pill that aims to compete with top-selling injections
The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J&J has said the new drug,...
-
Synthetic Biology & Advanced Compound Production3 months ago
Electrorheoimaging Helps Manage Droplet Viscosity in Real-Time
Electrorheoimaging Helps Manage Droplet Viscosity in Real-Time
-
Synthetic Biology & Advanced Compound Production3 months ago
HDX-MS Plus Computational Methods Provide Novel Approach to Study of Protein-Protein Interactions
HDX-MS Plus Computational Methods Provide Novel Approach to Study of Protein-Protein Interactions
-
Synthetic Biology & Advanced Compound Production3 months ago
Benchtop Bioreactor Simplifies Macrophage Manufacturing
Benchtop Bioreactor Simplifies Macrophage Manufacturing
-
Synthetic Biology & Advanced Compound Production3 months ago
CAR T Production Bottlenecks Best Tackled with AI, Automation, and Skilled Staff
CAR T Production Bottlenecks Best Tackled with AI, Automation, and Skilled Staff
-
Uncategorized3 months agoRead the latest issue of DDW
The new issue of DDW is now on its way to subscribers and available to read online. The Spring issue explores the next phase of obesity medications...
-
BioPharma Dive – AI / Data3 months agoAspen’s fresh Parkinson’s data; Aldeyra tanks following FDA rejection
Aspen Neuroscience presented positive Phase 1/2 data for its stem cell-derived therapy. Elsewhere, Aldeyra lost over half its market value following a rejection from the FDA.
An obesity drug deep-dive, and peptides move mainstream
RFK Jr. claims his calendar is publicly available. We’ve been trying to get it for a year
